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1 Introduction
1.1 The SEURAT-1 Cluster
The SEURAT-1 (Safety Evaluation Ultimately Replacing
Animal Testing-1) research program started at the begin-
ning of 2011 with the objective of improving safety assess-
ment without the need for animal experiments.[1] This E50
M project is co-financed by the European Union’s FP7
Health Program[2] and Cosmetics Europe.[3] A critical ele-
ment of this cluster is its focus on repeated dose toxicity
and the adoption of a mode-of-action (MOA) framework
based on an understanding of key biological events driven
by levels of exposure over time.[4–8] The SEURAT-1 cluster is
comprised of five complementary research projects
(COSMOS,[9,10] DETECTIVE,[11,12] HeMiBio,[13–14] NOTOX,[15–17]
Abstract : The aim of the SEURAT-1 (Safety Evaluation Ulti-
mately Replacing Animal Testing-1) research cluster, com-
prised of seven EU FP7 Health projects co-financed by Cos-
metics Europe, is to generate a proof-of-concept to show
how the latest technologies, systems toxicology and toxico-
genomics can be combined to deliver a test replacement
for repeated dose systemic toxicity testing on animals. The
SEURAT-1 strategy is to adopt a mode-of-action framework
to describe repeated dose toxicity, combining in vitro and
in silico methods to derive predictions of in vivo toxicity re-
sponses. ToxBank is the cross-cluster infrastructure project
whose activities include the development of a data ware-
house to provide a web-accessible shared repository of re-
search data and protocols, a physical compounds reposito-
ry, reference or “gold compounds” for use across the cluster
(available via wiki.toxbank.net), and a reference resource for
biomaterials. Core technologies used in the data warehouse
include the ISA-Tab universal data exchange format, REpre-
sentational State Transfer (REST) web services, the W3C Re-
source Description Framework (RDF) and the OpenTox
standards. We describe the design of the data warehouse
based on cluster requirements, the implementation based
on open standards, and finally the underlying concepts and
initial results of a data analysis utilizing public data related
to the gold compounds.
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Scr&Tox,[18–22] an infrastructure project (ToxBank[16,17,23]) and
a coordination action project (COACH), and involves over
70 different partners (see Figure 1).
SEURAT-1 is a complex, geographically distributed, multi-
disciplinary initiative. Within the SEURAT-1 cluster (HeMiBio
and Scr&Tox) there is a heavy emphasis on the develop-
ment of stem cell differentiation protocols to generate spe-
cific functional cell lineages as well as the use of primary
cells. In addition, cell engineering methodologies are being
developed to enable the use of these cells within a battery
of in vitro assays, utilizing high content and high through-
put automation wherever possible. An essential component
of this work is establishing best practices in the use, sourc-
ing and handling of the cells (ToxBank, Scr&Tox). Alongside
this cell biology research is the development of new mate-
rials to support the use of these cells in bioreactors that
mimic the 3D in vivo tissue structure (HeMiBio, NOTOX).
The cluster will make extensive use of omics approaches in-
cluding transcriptomics, proteomics, metabonomics, epige-
netics and fluxomics coupled with systems biology ap-
proaches to understand in more detail the dynamic biologi-
cal processes and to identify biomarkers that are predictive
of repeated dose toxicity (DETECTIVE, NOTOX). Considera-
ble resources are also being employed to understand bioki-
netics structure-activity relationships, and thresholds of tox-
icological concern for repeated does toxicity and adverse
outcome pathways (COSMOS). These critical technologies
will be combined to create a prototype platform for safety
assessment.
1.2 ToxBank
ToxBank is the cross-cluster infrastructure project whose ac-
tivities include the development of the ToxBank Data Ware-
house (TBDW), the selection of reference gold compounds
to support the mode-of-action framework, a physical com-
pounds repository, and resources to support the reliable
use of qualified biomaterials and protocols.
ToxBank Data Warehouse. The ToxBank data warehouse
provides a web-accessible shared repository of know-how
and experimental results to support the SEURAT-1 cluster.
The information within the TBDW is uploaded from the re-
search activities of the cluster partners as well as relevant
data and protocols from other sources, such as public data-
bases containing toxicogenomics data.
Gold Compounds Wiki. The underlying assumption of the
SEURAT-1 strategy is that we can identify MOAs that are de-
monstrably relevant to human toxicity based on existing
knowledge such as from adverse events of marketed drugs
in humans. To tackle the enormous breadth of chemical
space in compound selection, we concentrate on a limited
number of basic MOAs of toxicity. The SEURAT-1 goal then
becomes to establish in vitro assays to characterize and
represent these MOAs. Other issues such as prediction of
exposure or absorption, distribution, metabolism, and ex-
cretion properties although critical to predicting human
toxicity, are not determining factors per se for compound
selection. A limitation of an MOA-based strategy is that our











Figure 1. SEURAT-1 cluster program components and associated consortia. Design of the cluster (right) is based on the components of the
EU FP7-Alternative Testing Strategies call (left).
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is incomplete. The challenge and the opportunity are to
select compounds that will enable us to increase our un-
derstanding of MOAs. Approved compound-related infor-
mation is made publically available through the ToxBank
wiki.[24]
Physical compound repository. ToxBank is also responsible
for the collection of all chemicals and physical properties
for the evaluated standards. A framework for data quality
control was followed in order to guarantee the reliability
and uniformity of the collected data and their sources.
Biomaterials resources. The ToxBank cell and tissue bank
will provide an important open source service to specifical-
ly enable SEURAT-1 to identify suitable sources of cell lines
that will meet scientific criteria, ensure compliance with EU
and national regulations and provide assays which can be
taken up by industry without delays or blocks due to ad-
verse constraints on commercial exploitation. This work uti-
lizes standards recently developed as consensus amongst
stem cell scientists and biobanks.[25,26] The standards estab-
lished will be used in ToxBank to develop evaluation criteria
for suppliers of stem cell lines. Data from these suppliers
will be used to demonstrate compliance with best practi-
ces.
OpenTox. In developing infrastructure, such as the data
warehouse, the project is taking advantage of existing
open standards, particularly the OpenTox project.[16,17,27–31]
OpenTox developed a standard framework for interopera-
ble predictive toxicology support.[27] It makes extensive use
of REpresentational State Transfer (REST)-based web serv-
ices[32] for interaction with different geographically distrib-
uted services necessary to support predictive toxicology
data management, algorithms, modeling, validation, and
reporting. Extensions were made to the OpenTox frame-
work to support additional activities needing services by
ToxBank within SEURAT-1.
Open standards and the semantic web. ToxBank uses the
Investigation/Study/Assay (ISA) infrastructure open source
desktop software suite.[33] Ontologies and a domain-specific
ToxBank keyword hierarchy are used to enrich datasets by
adding enough experimental metadata to make the ar-
chives comprehensible and reusable.[16] The ISA2RDF tool
developed by ToxBank builds on the ISA-Tab framework
and facilitates conversion of investigation meta-data into
the semantic web standard RDF format.
Integrated data analysis. The data in the TBDW is being
collected to enable a cross-cluster integrated data analysis
leading to the prediction of repeated dose toxicity within
an MOA framework, based on a detailed understanding of
the technologies, requirements and work practices devel-
oped across the cluster. Semantic web technologies are
likely to be useful for integration of internal information
from SEURAT-1 with external information from database re-
sources around the world.[34]
1.3 Outline of the Paper
We describe here the initial development of the ToxBank in-
frastructure to house all the experimental results generated
from research activities carried out throughout the SEURAT-
1 cluster, as well as relevant public data. The design of the
system was based on a detailed understanding of the re-
quirements and work practices used across the cluster.
Technologies were selected to support the uploading and
searching of protocols and experimental data, as well as
future integrated data analysis needs. A series of standard
reference chemicals that stratify different MOAs related to
repeated dose toxicity have been selected. Anchoring the
cluster activities with these chemicals supports combining
the data from different projects for inference, analysis and
model building in a more productive way than an unstruc-
tured approach. Finally, a case study illustrating the use of
the selected compounds, the data warehouse, and analysis
methods is presented.
2 Materials and Methods
2.1 Gathering Requirements for the ToxBank Data
Warehouse
To build an effective solution for scientists across the
SEURAT-1 cluster, it was essential to understand the work
performed throughout the cluster. A methodology referred
to as contextual inquiry/design was used in the collection
of information for developing the requirements for the
TBDW.[35] Interviews were conducted with individual
SEURAT-1 scientists and notes were taken that recorded the
observations. In addition, each work task was documented,
which included the ordered steps necessary to complete
a task, how the event was initiated, and the reasons behind
the steps. All the tasks recorded throughout all the inter-
views were then consolidated by common task. A second
consolidation used the notes recorded from the interview
to create an affinity diagram (a hierarchical view of all
notes collected). The affinity diagrams and the sequences
(including any consolidated sequences) were used as the
starting point for the system design.
2.2 Strategy for Selection of Gold Compounds
ToxBank has created a quality-controlled curated chemin-
formatics database for gold compound reference standards
that can be used in the training and validation of in vitro
assays and in silico models for repeated dose toxicity. Gold
Compound selection was carried out early in the project to
facilitate decision making on project and assay design.
Reference compounds are selected primarily based on
their relevance to MOA in human toxicity. However, addi-
tional criteria apply generically to all compounds to ensure
their applicability for cell-based in vitro assays. These are
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are important to this project since omics profiling will be
used to characterize cellular responses to toxicants, and
comparison to previously observed profiles is one mecha-
nism for validating cellular assay systems. Criteria for ac-
ceptable physical properties ensure ease of handling in
vitro assays.
2.3 Public Data
Toxicogenomics has suffered from a shortage of large pub-
licly available standardized datasets.[36] Recently this situa-
tion has been addressed by the release of two such data-
sets: the TGP (TG-GATEs) dataset[37] and the DrugMatrix.[38]
Both have a uniform experimental design, assess a large
number of marketed drugs alongside standard toxicological
model compounds (such as acetaminophen) and provide in
vitro as well as in vivo data for comparative analysis. Both
datasets also include conventional toxicological data on
the compounds for predictive modeling and phenotype an-
choring. The TG-GATEs dataset includes information on 170
compounds, the DrugMatrix covers over 600 compounds
and there are 73 drugs in common between the two data-
sets. Paired compounds – i.e. , compounds that are closely
related structurally but nevertheless have different toxicity
profiles – comprise 16 pairs[36] and can be used as controls
to develop more accurate biomarker signatures for toxicity.
SEURAT-1 gold compound selection also includes the use
of paired compounds, e.g. DMNQ is structurally similar to
doxorubicin but has a more specific MOA. Data from the
public databases is being entered into the ToxBank data
warehouse to be made available in the ISA-Tab format.
The Comparative Toxicogenomics Database (CTD) is an
example of a derived resource that includes data analysis
tools and curated information about gene-chemical and
chemical-disease interactions that promotes understanding
about the effects of environmental chemicals on human
health.[39] This strategy allows data to be integrated to con-
struct chemical-gene-disease networks. Similar approaches
can be used to summarize data from the SEURAT-1 projects
and facilitate data mining and integrated data analysis.
2.4 Data Analysis
The CTD[39] (Supporting Information SI-Table 4) was used to
perform analysis of the biological similarity of gold com-
pounds, as measured by chemical-gene and chemical-gene
ontology (GO) associations which were common to at least
two gold compounds (Supporting Information SI 4.1–4.5).
Connections to 5623 genes were assessed in the clustering
analysis and 2290 GO categories were included. Clustering
of the compounds by gene association was compared to
clustering by GO associations and to the co-clustering of
chemicals by mode-of-action (MOA) (Figure 4). The same
chemical-gene and chemical – gene ontology associations
were evaluated for statistically significant associations to
MOA (Figure 5, Supporting Information SI Tables 5a/5b,
Supporting Information SI 4.1–4.3) using the Chi-squared
test.
Enrichment of gene ontology (GO) categories of genes
associated with the oxidizing agent mechanisms of action
(Figure 5A, Supporting Information SI Table 7) was carried
out using the Webgestalt tool.[40] Webgestalt uses the hy-
pergeometric test to determine whether the frequency of
occurrence of genes belonging to a GO-category is signifi-
cantly greater in the test set than in the reference list,
using all the proteins in the database with GO-annotations
as background. A network of proteins associated with
Asah1 protein (Figure 5C) was generated and analysis of
enriched GO categories in the network was performed with
the String 9.0 database (Supporting Information SI
Table 6).[41]
3 Results and Discussion
3.1 Requirements Analysis
A number of critical issues and ideas were drawn out from
an analysis for the requirements data (Tables 2a and 2b).
The need to develop a solution to manage the diverse pro-











Table 1. Generic criteria for selecting reference compounds.
Defined, confirmed structure and isomeric form
Stable to storage, light, freeze thaw
Soluble in buffer at 30 times the in vitro IC50 for toxicity
Solubility in DMSO 100  buffer solubility
Insignificant binding to plasticware
Available commercially at >95 % purity (>99 % preferred)
Non-volatile
Gene expression, proteomics, metabolomics/fluxomics, and/or epi-
genomics profiles known
Bioactivated (hepatotoxins)
Table 2a. Considerations in the development of the ToxBank pro-
tocols.
Protocols should cover each individual step, both the original re-
sults and any subsequent processed data
Protocols be assigned with a unique registration number for refer-
ence purposes
It should be possible to generate new versions of protocols
Protocols should cover any processing of the data (including com-
putational steps)
Protocols may be at different stages of development (research pro-
tocol versus Standard Operating Procedure or SOP)
Sharing of protocols should be sensitive to restrictive access for in-
tellectual property reasons or because a publication on the proce-
dure is underway
The ability to comment on and get alerts when new protocols are
uploaded
Peer-review process prior to uploading to the warehouse
Minimum effort for the end-user using any existing procedures
that are currently in place
Guidelines for writing of protocols should be provided
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a high priority as was the goal to enable SEURAT-1 investi-
gators to upload protocols with minimum effort. Important-
ly, a distinction is made between research protocol and
a more rigorously evaluated Standard Operating Procedure
or SOP (Table 2a). Peer-review is a central component of
the submission process for both protocols and data
(Table 2a and 2b). Providing for restrictive access support-
ing the protection of intellectual property and the potential
licensing of the protocols to other organizations (particular-
ly for the SMEs in the cluster) also forms a basis for the
design of the warehouse. In order to enable investigators
to reproduce or judge the quality of the data as well as to
support a future integrated analysis of the data, consistent
information in accordance with standards such as MIBBI[42]
is collected in all laboratories for the same experiment.
Handling data presented a number of complex problems
as a result of the diversity of the experiments being em-
ployed as well as the different workflows currently being
adopted across the cluster (Table 2b). The system should be
flexible enough to handle the diversity of data formats
being generated from spreadsheets to image files. The
warehouse provides access to the data from either the
Graphical User Interface (GUI) or via Application Program-
ming Interfaces (APIs) such as web services that could be
incorporated within workflow management software such
as KNIME.[43]
3.2 The ToxBank Data Warehouse
3.2.1 Design of the ToxBank Data Warehouse
ToxBank manages and provides access to all protocols and
experimental data across SEURAT-1 to support an integrat-
ed data analysis as illustrated in Figure 2. Once a new pro-
tocol is developed, documented and reviewed within the
partner’s organization, it can be uploaded to the TBDW
through the ToxBank GUI where additional information is
entered and associated with it.
This includes summaries of the protocol, identification of
the owner and authors, and a specification of who should
have access to the protocol.
In addition, keywords based on a cross-cluster keyword
hierarchy, are assigned to support searching and linking.
The ToxBank keyword hierarchy is a domain-specific set of
searchable terms to describe the data and protocols in the
TBDW (see Supporting Information SI 2.4. for details).
Investigational data generated by the research program
is prepared and reviewed by SEURAT-1 investigators using
the ISAcreator[33] tool to enter the experimental design,
with the steps of the investigation each linked to SEURAT-
1 protocols as well as to any raw or processed data. This
ensures the data is in a defined and standardized format
agreed across the cluster. Where an investigation is needed
that is not covered by existing templates, a new investiga-
tion template is generated that is acceptable across the
entire cluster. ISA-Tab archives of the investigational data
are loaded into the TBDW in a similar manner as protocols.
The protocols and data can be accessed via a simple free
text search or through a browse function that returns sum-
maries of any information matching the query. The proto-
cols or investigation data can then be viewed or download-
ed directly along with links to related information, such as
the ToxBank gold compound[24] or biomaterials wikis (con-
taining information on the gold compounds or the bioma-
terials being used across SEURAT-1). When the investigator
does not have permission to view a specific protocol or in-
vestigation data, only the summary information is dis-
played. The investigator is then free to contact the investi-
gator who loaded the information directly to the TBDW to
request access rights. Once an agreement is in place, the
investigator who uploaded the information modifies per-
mission levels accordingly. A regularly scheduled email
alerting scientists who have registered an interest in a spe-
cific type of information is sent out across SEURAT-1.
Figure 2 summarizes the TBDW data and protocol manage-
ment operations showing the phase I system that is cur-
rently implemented alongside a future phase II that will in-
clude an integrated data analysis.
3.2.2 Application of Standards to Dose-Response Analysis
The Microarray Quality Control (MAQC) consortium second
phase (MAQC-II) was centered on the development and val-
idation of genomics biomarkers and validating microarray-
based models aimed at predicting toxicological and clinical
end points[44] . A key take-home message was that classifier
protocols need to be more tightly described and executed.
The TBDW, based on cluster-wide requirements analysis, fa-
cilitates this goal by ensuring that experimental layouts, ob-
jective metrics for data quality and conditions are captured
together with SOPs for each step. For omics studies, refer-
ence dose-response analysis is being performed and care-












Table 2b. Considerations in annotation of data in the ToxBank
data warehouse (TBDW).
Data should always be annotated with protocols, both for the orig-
inal results and any subsequent processed data
Data files should be assigned with a unique registration number
Data access should be sensitive to proprietary needs
Possible to search and download any protocol or investigation
data
Both the original results and any subsequent processed data
should be included
Peer-review process for data prior to uploading to the warehouse
Omics data should comply with the MIBBI minimum information
standards
Data will be in the ISA-Tab format
Providing information on the cells, reagents, suppliers, and stan-
dard compounds was also highlighted as important activities
Guidelines for submitting data should be provided
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ISA-Tab templates can store dose-response information;
which together with common SOPs enables us to calculate
aggregate values (e.g. IC50) from the dose-response data in
a uniform way to correlate different endpoints, to identify
experimental conditions having the largest impact on out-
comes and to compare relative potency of compounds
across different in vitro systems. Within these bounds, each
consortium works towards SEURAT-1 goals independently.
3.3 ToxBank Data Warehouse Architecture and Technologies
The ToxBank system consists of a set of web services, pro-
viding access to protocols and data, a search service, and
a Web GUI application, offering user-friendly access to the
above functionality. The web services, developed by part-
ners in Java and Ruby programming languages, currently
share a single machine but can also be run on geographi-
cally dispersed servers, and communicate via the Internet
or on a private network or secured cloud infrastructure.
This design is expected to facilitate adding new services of
any kind, for example supporting different data types. Tox-
Bank adopts the OpenTox framework design,[27–31] based on
the following technological choices (i) the REpresentational
State Transfer (REST)[32] software architecture style allowing
platform and programming language independence and fa-
cilitating the implementation of new data and processing
components; (ii) a formally defined common information
model, based on the W3C Resource Description Framework
(RDF)[45] and communication through well-defined interfa-
ces ensuring interoperability of the web components; (iii)
authentication and authorization, allowing defining access
policies of REST resources, based on OpenAM;[46] (iv) 4store
(http://4store.org) triple store as a backend for the investi-
gation service. The protocol services use MySQL relational
database as a backend. Both the protocol and investigation
service APIs support RDF serialization of the relevant re-
sources, regardless of the specific backend technology











Figure 2. Overview of the currently operational (Phase I) and future (Phase II) ToxBank Data Warehouse data and protocol management
operations. SEURAT-1 cluster project members share protocols, SOPs and experiment results according to bilateral agreements brokered
via the TBDW. All projects upload their raw and processed data into this data warehouse using the ISA-Tab architecture.
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pendent of the underlying implementation, enabling dy-
namic selection of the most appropriate backend technolo-
gy, without modifying the API. The API is described at
http://api.toxbank.net/. It is currently used by the ToxBank
web GUI and an ISAcreator extension to assess ToxBank
services, and potentially could be used for ToxBank integra-
tion with other environments such as Bioclipse[30] . The im-
plementation of the client as well as the protocol and in-
vestigation service is open source and available at https://
github.com/ToxBank.
ToxBank‘s data warehouse concept has many options for
a service or business model tailored to industry members‘
specific requirements and needs. Choices vary from a cus-
tomized deployable in-house system to a completely out-
sourced service solution. The distributed, modular, secure
and open standards-based environment lends itself well for
the needs of pharmaceuticals, agrochemicals and consumer
products industrial customers, especially in the cloud-com-
puting age when monolithic solutions are being replaced
by more agile ones.
ISA-Tab is an open standard developed to provide a con-
sistent way of representing the meta-information about an
experiment.[33] It is being used to represent the diverse
types of experimental data within the TBDW. Data access
and upload procedures are defined by an investigation API.
Data is uploaded in ISA-Tab format and specific data quer-
ies are performed with the SPARQL query language. REST
operations are available for accessing individual investiga-
tions, studies, assays and data files and enable communica-
tion with the TBDW. To collect investigation data in the ISA-
Tab format, the ToxBank consortium selected to use the
ISAcreator open source tool. The tool provides a series of
forms for entering the information and can generate an ar-
chive of the entire investigation in the ISA-Tab format. The
tool has been customized to integrate with resources spe-
cific to the SEURAT-1 cluster, such as users and organiza-
tions as well as SEURAT-1 protocols and common key-
words.
The core standard used in the design of ToxBank to pro-
vide interoperability is, however, the Resource Description
Framework.[45] RDF is the underlying technology developed
by the World Wide Web Consortium (W3C) to enable a Se-
mantic Web.[47] It is developed to make a Linked Resource
approach possible, where information on the Internet is
machine readable. RDF is the W3C proposed technology to
link data on web pages, small resources or large databases,
in a unified way. These Linked Resource or Semantic Web
approaches are being adopted by the international life sci-
ences community, such as the Health Care & Life Science
interest group,[48] and EU projects such as OpenTox[27–31]
and Open PHACTS.[49] The standards support many different
applications; by adopting them we ensure that ToxBank
will be fully interoperable with many other life science proj-











Figure 3. Screen captures of the ToxBank Data Warehouse graphical user interface for uploading, searching, browsing, and downloading
cluster protocols and data (currently in the beta-testing phase), along with the ISAcreator software[33] for preparing an investigation data-
set. Links to compound and biomaterials information in the ToxBank wiki (wiki.toxbank.net) are provided for all protocols and data sets.
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ISA-Tab framework facilitating conversion of investigation
meta-data into the semantic web standard RDF format
(https://github.com/ToxBank/isa2rdf).
SEURAT-1 is a complex, multi-disciplinary initiative involv-
ing the collaboration between over 70 international part-
ners. A common organization and definition (including any
synonyms) of important concepts is an essential infrastruc-
ture enabling activity. The ToxBank consortium has created
a keyword hierarchy that is used in the TBDW. In addition
to its use in facilitating collaborations, the keyword hierar-
chy is used to support searching, browsing and linking of
resources within the warehouse. When information is up-
loaded into the TBDW, terms will be selected from this hier-
archy and linked to protocols and investigation datasets in
the warehouse.
The ToxBank GUI is a front-end user interface for the re-
pository services defined by the ToxBank API. It is a stand-
alone web application allowing users to log in, review exist-
ing protocols and investigations, and to upload new proto-
cols and investigations. The GUI serves as an intermediary
between the user and the repository services. Figure 3 pres-
ents example screens from the ToxBank GUI illustrating dif-
ferent scenarios for uploading information and searching
the content.
3.4 Gold Compound Selection
3.4.1 Overview
The proposed gold compound collection includes a limited
sample of compounds for each of the major chemical
mechanisms, as illustrated in Table 3. Marketed drugs with
well-characterized adverse events in humans were the start-
ing point for constructing this list. In many cases, however,
the marketed drugs may have multiple activities, such as
the combination of alkylating and oxidizing activities of
acetaminophen. For this reason, we have added com-
pounds that have well-characterized, narrow modes-of-
action (MOA) to the collection in order to specifically repre-
sent MOAs known or presumed to commonly underlie
human adverse events.
3.4.2 Alkylating Agents
Alkylating agents are distinguished in the first instance by
the target nucleophile. Thiols are the cellular nucleophiles
generally most reactive to alkylation, and glutathione is the
most abundant thiol by several orders of magnitude. Alky-
lation of glutathione is frequently cited as leading to loss of
cellular reduction potential, with cytotoxicity resulting from
subsequent formation of free radicals.[50] However, thiols at
the active site of some proteins may be activated 100-fold
or more as nucleophiles compared to glutathione.[51] While
glutathione adducts will normally be the dominant alkylat-
ed species in an absolute sense, adducts with more reactive
protein thiols may be dominant in a relative sense. The bal-
ance is determined by the intrinsic reactivity of the protein
thiol versus the glutathione and the efficiency of catalysis
of glutathione alkylation by glutathione transferase.[52] Exist-
ing data comparing the reactivity profiles of thiol reagents
across the spectrum of cellular thiols is sparse, but reagents
to quantify these profiles are available, and proteomic char-
acterization of these profiles will be a significant contribu-
tion to the elucidation of the key molecular targets of
these reagents.[53,54]
Alkylating agents are often formed in situ by oxidation,
and alkylating activity is frequently therefore associated
with redox activity. This is the case for quinones such as
the acetaminophen-NAPQI redox couple.[55] In order to eval-
uate the effects of alkylation alone, a pure alkylating agent,
iodoacetamide, has been included in the gold compound
collection.
Aflatoxin B1 is included as a standard for alkylation be-
cause it is an exception in targeting lysine amino groups in-
stead of thiols. It is activated by oxidation to an epoxide,
which is subsequently hydrolyzed to a vicinal dialdehyde,
which in turn forms bidentate adducts with amines.[56,57]
This toxicant also targets alkylation of DNA nitrogens, but
the study of this latter reactivity is outside the current
scope of the SEURAT-1 project.
3.4.3 Redox Agents
Redox agents with reduction potentials in the range be-











Table 3. Classification of gold compounds by biochemical mechanism.
Mechanism Representative Compounds/Receptors
Alkylating agents
* Thiol reagents Acetaminophen, allyl alcohol, iodoacetamide
* Lysine reagents Aflatoxin B1
Redox agents
* High reduction potential (strongly oxidizing) Acetaminophen, chlorpromazine
* Low reduction potential (weakly oxidizing) Doxorubicin
Free radical agents Carbon tetrachloride
Promiscuous compounds Chlorpromazine, amiodarone, valproic acid
Promiscuous receptors Nuclear hormone receptors, hERG ion channel
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be relevant to cellular biochemistry.[58] This is an enormous
range of reactivity, but the range can be split into two fun-
damental regions based on the reduction potential of cyto-
chrome c. When oxidizing agents with reduction potentials
lower than that for cytochrome c are reduced by NADH or
glutathione, the reducing equivalents can be passed into
the electron transport chain at complex III so that at least
some of the energy from the reduction is preserved and
converted to ATP.[59–62] Toxicity may be assumed to arise be-
cause this process is not subject to regulation as it is in the
cellular electron transport chain, and levels of NADH can be
depleted below those necessary to maintain the cellular re-
duction potential. Direct reoxidation of the reduced form
by oxygen aids in driving the cell towards an overall oxidiz-
ing environment and results in total loss of the energy
stored in NADH.
In contrast, strong oxidizing agents such as NAPQI (the
oxidized form of acetaminophen) trap NADH but cannot be
reoxidized by cytochrome c and therefore block the entry
of reducing equivalents into the electron transfer chain.
This depletes the mitochondrial membrane potential and
wastes the chemical energy stored in the NADH. Reoxida-
tion of these agents requires strong oxidizing systems such
as the cytochrome P450’s so that toxicity is limited to me-
tabolizing organs such as liver and kidney.[55,63,64]
3.4.4 Free Radical Agents
Many alkylating and redox agents have been shown to
induce lipid oxidation, commonly taken as evidence for
free radical formation, which often arises indirectly from de-
pletion of glutathione and NADH. The relative importance
of 1-electron vs. 2-electron reactivity has not been assessed
in most cases, however. We have selected carbon tetra-
chloride as a standard because the initial reactive species
has been shown to be the trichloromethyl free radical.[65–67]
Although the initiating factor is a free radical, a major
product of this reactivity is the oxidation of fatty acids with
the formation of 4-hydroxynonenal, which is a classic thiol
alkylating reagent.[67,68] The question concerning the role of
free radicals in toxicity, therefore, is to what extent one-
and two-electron reactivities affect different cellular targets.
It must be considered, however, that differences in the ef-
fects of carbon tetrachloride compared to simple alkylating
agents such as iodoacetamide may be more related to the
extreme hydrophobicity of carbon tetrachloride and the re-
active species derived from it.
3.4.5 Promiscuous Compounds
Chlorpromazine and amiodarone bind to phospholipid bi-
layers, which is the source of the pharmacological activity
for these drugs.[69,70] They are also relatively potent inhibi-
tors of ATP synthase, which is a membrane-bound pro-
tein.[71] While reactive metabolites are produced by chlor-
promazine, amiodarone is not an obvious source of chemi-
cal reactivity. Tamoxifen, developed as an estrogen receptor
(ER) antagonist, is also an ATP synthase inhibitor without
obvious chemical reactivity ; and both tamoxifen and amio-
darone inhibit additional points in the electron transport
chain, even though the proteins inhibited are disparate in
chemical structure.[71] These results together imply a role
for membrane disruption by highly hydrophobic com-
pounds in cytotoxicity, and oxidative phosphorylation ap-
pears to be sensitive to this type of inhibition.
We define compounds in this class as promiscuous in the
sense that disruption of membrane function presumably af-
fects multiple targets. There is some selectivity in the inhib-
ition profiles, however. Additionally, while valproic acid is
highly promiscuous in its activities at the high exposures
commonly encountered for this drug, it is also a fatty acid
analogue and there may be some selectivity for its inhibi-
tion of fatty acid oxidation compared to other toxicants in
this class.[72] Additionally, valproic acid is a selective histone
deacetylase (HDAC) inhibitor and under consideration as
a drug for cancer treatment.[73]
3.4.6 Promiscuous Receptors
In addition to promiscuous ligands, there are promiscuous
receptors that are relatively nonselective in binding ligands.
The hERG ion channel is an archetypical example and is in-
cluded as a target for cardiotoxicity standards.[74] Promiscui-
ty of other major protein classes is being assessed quantita-
tively in the Toxcast program of the EPA and is the basis of
selecting the proteins below.[75]
Nuclear factors Nrf2 and Hif-1a are indicators of reduc-
tive and oxidative equivalents, respectively, available to the
cell. They represent promiscuous responses in the sense
that changes in the availability of redox equivalents are in-
duced via a wide array of mechanisms, including alkylating
and redox active toxicants described above.[76–81]
Screening assays for nuclear hormone receptor activation
also demonstrate the high promiscuity of several of these
systems. Based on the profiles below, we propose to target
the CAR, PXR, LXR, and AhR nuclear hormone receptors for
characterization based on a common theme of regulation
of lipid and steroid metabolism in hepatocytes.[75] Addition-
ally, to responding to xenobiotics, these receptors have
major roles in cholesterol, bile acid, and fatty acid homeo-
stasis. Compounds under consideration are listed in Table 4.
3.4.7 Energy Metabolism
Disruption of cellular energy status via loss of reduction po-
tential, disruption of mitochondrial membrane gradients,
and inhibition of ATP formation are commonly cited as
causes of cytotoxicity.[50,55] Toxicities associated with drugs,
however, frequently have multiple potential MOAs, where-
as, as pointed out above, an MOA-based approach to pre-
diction of toxicity must rely on an understanding of dis-
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pounds that are selective for key points of interaction in
the energy metabolism pathways so that we can create
profiles representative of these more discrete MOAs. Com-
parison of these to less selective toxicants will help us un-
derstand which MOAs are dominant causes of toxicity for
the more complex compounds.
The thiol of glyceraldehyde phosphate dehydrogenase is
highly reactive to alkylating agents, and inactivation of this
enzyme would be fundamental to production of ATP and
cellular survival with glucose as energy source.[82] Thus, we
have included iodoacetamide as a reference compound
that is a simple thiol reagent without additional redox ac-
tivity and has been well-characterized as an inhibitor of gly-
colysis.[51,83]
Similarly, DMNQ is proposed as a standard for redox cy-
cling for comparison to doxorubicin without the additional
DNA intercalating activity of the latter compound, which
complicates interpretation of MOA of toxicity. As described
above, quinones such as DMNQ and doxorubicin cause the
simple two-electron oxidation of NADH, without accompa-
nying alkylating activity.[61] This reaction in turn depletes
the cellular reduction potential, turning on redox-sensing
receptors such as Nrf2.[80] At high concentrations, it is possi-
ble that these oxidizing agents will cause the electron
transport chain to run in reverse and deplete ATP directly,
as is observed for mitochondrial uncouplers.[84]
In contrast to quinones with low reduction potentials,
strongly oxidizing quinones such as the acetaminophen-
NAPQI couple trap NADH but cannot be oxidized by cyto-
chrome c and therefore block the entry of reducing equiva-
lents into the electron transfer chain. This depletes the mi-
tochondrial membrane potential, the cellular redox poten-
tial, and the energy stored in NADH.[63] A central question
for understanding MOAs of cytotoxicity is whether strong
oxidizing agents are intrinsically different from weak oxidiz-
ing agents at the point at which NADH levels are depleted.
Finally ATP synthase is a common target of hydrophobic
toxicants with promiscuous activity, presumably reflecting
a sensitivity of this enzyme to membrane disruption.[71]
3.4.8 Lipid Metabolism
Compounds with well-characterized effects on lipid metab-
olism in humans are commonly associated with toxicities of
chemically reactive or promiscuous nature, which obscures
the evaluation of phospholipidosis and cholestasis, for ex-
ample, as protective, as an additional toxicity, or as
a benign reaction to a xenobiotic. Thus, we have selected
additional compounds that have minimum complicating as-
sociated relativities, with the purpose of assessing the rele-
vance of long-term exposure to accumulated lipids in
human toxicity. To the extent that lipid accumulation turns
out to be a benign adverse event, these standards will be
negative controls.
These chemically non-reactive standards include fluoxe-
tine, a serotonin reuptake inhibitor that causes phospholi-
pidosis by physical association with phospholipids.[85] Bo-
sentan is an endothelin receptor antagonist that was select-
ed for causing cholestasis via competitive inhibition of the
bile salt export pump (BSEP).[86] Finally, dirlotapide is a com-
pound designed to block uptake of fatty acids in the gut
by inhibition of the Microsomal Triglyceride Transfer Protein
(MTTP). Inhibition of hepatocyte MTTP by dirlotapide can
be used to induce steatosis.[87]
3.4.9 Tissue Repair and Fibrosis
Acetaminophen is generally considered a very safe drug on
repeated low dose exposure but can progress rapidly to
liver failure at exposures above a safe threshold. This is
consistent with classic models of tissue repair in toxicant-in-
duced tissue injury in which injury progresses to organ fail-
ure when the capacity for repair is exceeded.[88] A funda-
mental question for prediction of repeated dose toxicity is
why there is no fibrotic response to necrosis for this com-
pound at doses below this safe threshold whereas other
chemically reactive cytotoxins such as CCl4 and allyl alcohol
do cause fibrosis.[89,90]
As an aid to understanding the causes of fibrosis inde-
pendent of the complicating effects of chemical reactivity,
methotrexate was selected as a reference pro-fibrotic com-
pound with a well-defined MOA not related to chemical re-











Table 4. Nuclear hormone receptor (NHR)-directed standards (tentative[a]).
Compound NHR Comment




AHR DRE-independent repression of cytokine mediated acute phase response.
GNF361 AHR Antagonist of both DRE-dependent and -independent activity.
Phenobarbital CAR Induction of metabolizing enzymes and epigenetic alterations of DNA. Mechanism of CAR activation
not clear.
Rifampicin PXR Induction of metabolizing enzymes. Gene expression profiles for human hepatocytes available.
T0901317 LXR LXRa/b nonselective agonist induces lipogenesis, steatosis, and secretion of LDL.
[a] The compound selection strategy for NHRs is still under discussion.
56 www.molinf.com  2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Mol. Inf. 2013, 32, 47 – 63
Full Paper P. Kohonen et al.
hibitor that acts primarily to block DNA synthesis by inhibit-
ing conversion of dUMP to dTMP.[93]
3.4.10 The Gold Compounds Wiki
The Gold Compounds Wiki (GCW) consists of reviewed in-
formation on the set of compounds that form the basis for
the SEURAT-1 MOA strategy and is made publicly available
for perusal and re-use through the ToxBank wiki.[24] Each
reference compound is annotated with a broad series of
characteristics, driving the planning of the experiments, its
use, and the successive interpretation of the results. The
collection of data, structures and properties, represents
a wide set of compounds, and investigators can take ad-
vantage of such a scheme to increase the number of refer-
ence compounds later on when the needs of further chem-
icals may appear. The TBDW entries for protocols and data
entries are linked to the GCW as well as to biomaterials in-
formation, which will be made publicly available later in
a similar manner.
3.5 Data Analysis of Public Information on Gold Compounds
The CTD was used to perform analysis of the biological
similarity of gold compounds, as measured by gene and
gene ontology (GO) associations with connections to at
least two of the 12 gold compounds in the CTD.[39] Cluster-
ing of the compounds by gene association (n = 5623) was
compared to clustering by GO-associations (n = 2290) and
to the co-clustering of chemicals by mode-of-action (Fig-
ure 4A and 4B). Structures of the reference compounds
used in the data analysis are provided (Supporting Informa-
tion SI 3, Figure S2).
Clustering of the 12 gold compounds by gene associa-
tion produces an unstructured tree with few higher-level
bifurcations (Figure 4A). In contrast, GO-association group-
ed the chemicals into three distinct clusters (Figure 4B). The
uppermost cluster contains chemicals with diverse MOAs
related to oxidation, such as beta-oxidation and com-
pounds such as acetaminophen and sodium valproate. The
middle cluster contains chemicals mostly having the thiol-
reagent MOA, containing 75 % of chemicals with that MOA.
The lower-cluster contains both chemicals with the phos-
pholipid binding MOA. Therefore GO associations seem to
cluster compounds according to the MOA, at least in this
set of chemicals. The better performance of GO-associa-
tions may be because individual GO categories are associat-
ed to more chemicals (n = 5.5) on the average than are
genes (n = 2.5).
In addition, the specificity of association of individual
genes and GO categories to literature-based MOAs (Table 5)
were determined using the Chi-squared test (Table 6a and
6b, SI Tables 5a and 5b). The assignment of MOAs from the











Figure 4. A) A heatmap with filled squares representing the assignment of a MOA category. Compounds are clustered according to the
5,341 genes based on links to genes in the Comparative Toxicogenomics Database (CTD) (http://ctdbase.org/).[39] B) A heatmap with filled
squares representing the assignment of a MOA category. Compounds are clustered according to 2290 GO categories derived based on
links to genes in the CTD. The MOA categories are clustered according to the MOA profile across the compounds (Table 5).
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GO category assignment for the same compounds. A Chi-
squared test with Yates adjustment was used to assess the
association between the assigned MOAs and the genes/GO
categories. The Yates adjustment was used because of the
small number of compounds in this study. Gene/GO cate-
gories associations with the assigned MOAs were rejected
with p-values greater than 0.075; however, those associa-











Table 5. Summary information for reference standards. The MOAs and human adverse events for compound standards, extracted from the
GCW of SEURAT-1 reference compounds. Information of the target organ(s) is also included. Compound suppliers and product numbers
are provided to ensure that all labs are using a common compound source.
Compound Target
organ
MOA Adverse event Source and prod-
uct no.
Drug Standards for Reactive Compounds
Acetaminophen
CAS # 103-90-2






















Liver Thiol reagent, oxidizing agent, free radical,
lipid binding, ATP synthase inhibition








All Redox cycling (MOA standard) Sigma Aldrich
# D5439
Promiscuous Ligands and Receptors
Sodium valproate
CAS # 99–66–1
Liver Inhibition of multiple pathways, including b-
oxidation










Heart hERG channel blocker Arrhythmias Sigma Aldrich
# M5060
MOA Standards for Oxidative Phosphorylation
Rotenone
CAS # 83-79-4








All Proton gradient uncoupler (MOA standard) Tocris Bioscience
# 0453
MOA Standards for Lipid Metabolism
Bosentan
CAS # 147536-97-8





Liver MTTP inhibition Steatosis
Fluoxetine
CAS # 54910-89-3





















All Protein synthesis inhibitor (standard for electron microscopy) Invivogen
# ant-hg-10p
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dition, only MOAs that were assigned to at least two gold
compounds were used in this analysis. This resulted in sig-
natures for two MOAs: phospholipid binding and oxidizing
agent.
Connections of the genes signatures associated with
a particular MOA (Table 6a) to gene ontology categories
were identified (Figure 5A). Gene ontology (GO) category
enrichment analysis of the genes associated with the oxi-
dizing agent MOA (Table 6a) using the Webgestalt tool[40]
revealed an overabundance of genes associated with the
GO molecular function (MF) Oxidoreductase activity
(GO:0055114, adjP<0.0175) and Electron carrier activity
(GO:0009055, adjP<0.0175).
Two genes are associated with the phospholipid binding
MOA (Table 6a, Supporting Information SI Table 5a) and the
asah1 (N-acylsphingosine amidohydrolase, Yates adjusted
Chi-squared p-value<0.02) gene has a lipid-related func-
tion. The STRING 9.0 protein interaction and associations
database[41] was used to construct a network of directly as-
sociated proteins around Asah1 protein. A GO enrichment
analysis of the proteins in the Asah1 network reveals en-
richment of the GO sphingoid metabolic process
(GO:0046519, FDR p-value<2.67  10–14) (Figure 5C).
The GO categories associated with MOAs seem to be less
mechanistically related to the MOA that was used for deriv-
ing them, although many appear to be biologically relevant
(Table 6b, SI Table 4b). However, the Chi-squared p-values
of GO-associations are also lower than the associations
with genes, possibly because each GO category is, on the
average, associated with a larger number of chemicals in
the set of gold compounds. A difference in the average
number of associations of 5.5 to 2.5 can be significant be-
cause, in the analysis, the absence of associations to non-
MOA related chemicals is equally significant to the associa-
tions to chemicals with the target MOA. A more compre-
hensive study with a larger set of compounds would help
to further define thresholds of statistical significance and
best practices for connecting MOAs to genes and path-
ways.
Bar plots of the frequency of association of the dao (D-
amino-acid oxidase) gene encoding a peroxisomal protein
with chemicals reveals SEURAT-1 gold compounds among
the top associated compounds (Figure 5B). Pretreatment of
mice with the peroxisome proliferator clofibrate (CFB) pro-
tects against Acetaminophen (APAP)-induced hepatotoxici-
ty.[94] The protective mechanism is thought to occur via the
activation of the nuclear peroxisome proliferator activated
receptor-alpha (PPARa). PPARa affects the reaction of clofi-
brate co-treated with Acetaminophen which affects the ex-
pression of dao mRNA. The dao gene is also annotated
with the enriched oxidoreductase activity GO molecular
function (Figure 5A), corresponding with Acetaminophen
MOA related to oxidizing agent activity.
This illustrates how association of the oxidizing agent
MOA-related genes with the oxidoreductase activity GO
category confirms that at least this MOA can be retrieved
by analyzing the high-throughput data submitted to the
CTD for the 12 compounds. The data consists mainly of un-
biased genome-wide gene expression studies.
The asah1 gene, most significantly associated with the
phospholipid binding MOA, is related to the synthesis and
degradation of ceramide into sphingosine and fatty acid,
also showing recovery of the association to the MOA. The
two gold compounds associated with asah1 are fluoxetine
and aminoadrone (Figure 5D). Of these chemicals aminoa-
drone also causes steatosis and necrosis of the liver. Differ-
ences in the associations to these chemicals may help ex-
plain why aminoadrone is more toxic. One of the goals of
SEURAT-1 integrated data analysis will be to find out what
biomarkers signal the adverse outcomes and to understand
why chemicals with a similar MOA sometimes behave dif-
ferently in vivo. It is possible that in vivo repeated-dose ad-
verse outcome prediction needs to take into account the
basic MOAs of the compounds and possibly also interac-
tions among different MOAs.
The analysis results thus confirm the assumed MOAs of











Table 6a. The most strongly associated genes when comparing
the MOA and gene profile across the 12 compounds in the CTD
database using the Chi-square test. A Yates adjusted p-value of
<0.075 was considered tentatively significant and p-value <0.02 is







Oxidizing agent BAG4, CYP2C, CYP3A11, NDUFS3, CAR2,
CHTF18, STS, NFATC1, MAPKAPK2, SLC19A1,
CCNF, DAO, COX8A, KCNN2, FCGR2B, FOSB,
ORM1, ORM2, MCM5, LEP, PHYH
Table 6b. The most strongly associated GO categories when com-
paring the MOA and gene profile across the 12 compounds in the
CTD database using the Chi-squared test (SI Table 5b). A Yates ad-
justed p-value of <0.075 was considered tentatively significant
and p-value <0.02 is displayed in bold-type (Supporting Informa-
tion SI Table 5b).
Mode-of-Action (MOA) Gene Ontology (GO) category
Phospholipid binding GO:0006813 (potassium ion transport),
GO:0033695 (oxidoreductase activity,
acting on CH or CH2 groups, quinone or
similar compound as acceptor),
GO:0034875 (caffeine oxidase activity)
Oxidizing agent GO:0019748 (secondary metabolic pro-
cess),
GO:0030307 (positive regulation of cell
growth),
GO:0000080 (G1 phase of mitotic cell
cycle), GO:0051318 (G1 phase)
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agent MOAs, although these are fairly well established in
the literature (Table 5). In this way the CTD derives and
stores curated and statistically significant connections be-
tween chemicals, genes and GO categories; providing
gene-level descriptions of the chemicals’ MOAs.
4 Conclusions
The currently proposed “21st Century toxicity testing para-
digm” is based on a mode-of-action framework that relies
on the understanding of biological pathways and mecha-
nisms of action that underlie the toxicity of chemicals in
vivo.[7] The SEURAT-1 program is developing a MOA-based
strategy for animal-free replacements of repeated-dose tox-
icity testing. This paper has presented on-going work from
the ToxBank infrastructure project which is supporting the
research activities of the SEURAT-1 cluster, including the se-
lection of standard reference compounds that stratify dif-
ferent MOAs associated with repeated dose toxicity, that
are potentially relevant across multiple endpoints and
organs, such as liver, kidney, heart and the brain. The stan-
dard reference chemicals will be used within the other con-
sortia to ensure the experimental results from the different
research activities can be compared.
The ToxBank data warehouse will house SEURAT-1 gener-
ated results and protocols as well as relevant data from
outside the cluster. The warehouse has been developed to
enable any future integrated data analysis through the use
of RDF and REST-based web services. The warehouse was
designed to support research scientists working on the de-
velopment of replacements to the current repeated dose
toxicity tests; however, as the project develops more em-
phasis will be placed on the use of these approaches to
support stakeholders from industry and regulatory agencies
for risk assessment purposes.
A goal of the SEURAT-1 project is to investigate the ap-
plicability of model systems for uncovering chemical-MOA
associations and the robustness of the associations across











Figure 5. A) Enriched gene ontology (GO) categories of genes associated with the oxidizing agent MOA (Table 6a, SI Table 5a) using the
Webgestalt tool.[37] Terms in grey have a significance, after multiple testing correction, below adjP<0.05 (Supporting Information SI
Table 6). B) The gene dao (D-amino-acid oxidase) is associated with a number of the gold compounds according to the Comparative Toxi-
cogenomics Database (CTD), sorted by frequency of chemical-gene associations.[36] C) Protein-protein association network around the
Asah1 (N-acylsphingosine amidohydrolase) protein from String 9.0. database (Supporting Information SI Table 7).[38] D) Compounds associat-
ed with the asah1 gene in the CTD.[39]
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to primary cell cultures to highly developed bioreactors. In
order to achieve this both the descriptions of experimental
metadata and the most relevant results need to be standar-
dized with the use of ontologies and the SEURAT-1 keyword
hierarchy. Semantic web technologies can enable flexible
and on-going data mining of the entire dataset, as new
data is generated and submitted to the ToxBank data ware-
house, and can facilitate creating connections to external
data such as the CTD and the processed data from the
DrugMatrix and TG-GATEs repositories.
Similarly, while repeated dose toxicity is a focus for
SEURAT-1, in many cases the biological rationale behind re-
peated dose toxicity is not fully understood. In the context
of the MOA for toxicity, however, there are only two possi-
bilities: either the MOA leading to repeated dose toxicity is
the same as that for acute toxicity or it is different. To illus-
trate, carbon tetrachloride at high doses causes acute wide-
spread hepatic necrosis while low repeated doses lead to
fibrosis, which is still a response to necrosis, just a more
limited and localized necrosis. This is an example where the
primary MOA is the same for both acute and repeated
dose toxicity. The repeated dose toxicity of phenobarbital,
in contrast, is proposed to result from changes in locus-
specific DNA methylation patterns, an MOA distinct from
acute biological responses.[8]
The compound selection strategy must therefore be
based on an understanding of MOAs that underlie repeated
dose toxicity so that these MOAs are adequately represent-
ed in the in vitro assays. The difficulty behind this state-
ment is again illustrated by carbon tetrachloride. While
carbon tetrachloride-induced fibrosis is presumably a re-
sponse to cell death, many compounds cause hepatic cell
death, but not all of them cause fibrosis upon repeated
low exposures. The challenge is to understand and derive
from cellular model system MOAs at a level of granularity
sufficient to distinguish acute versus chronic effects in vivo.
SEURAT-1 gold compounds with diverse chemical struc-
tures (Supporting Information SI Figure S2) and MOAs
(Table 5, Figure 5) were clustered by chemical-gene and
chemical-GO association from the CTD. Clustering of the
compounds by GO association grouped together com-
pounds with a similar MOA. Associations of genes to the
SEURAT-1 gold compounds from the CTD come mainly
from microarray studies, illustrating the value of gene ex-
pression studies in generating a large number of chemical-
gene associations. Microarray studies also generate more
unbiased chemical-gene associations, since typically the ex-
pression levels of all the protein-coding genes in the
genome are measured. For validation purposes associations
uncovered by the toxicogenomics analysis would need to
be experimentally verified.
Since the SEURAT-1 gold compounds have fairly well es-
tablished MOAs (Table 5) the most significant result of the
CTD-based data analysis is that unbiased high-throughput
data also reflects the MOAs obtained from literature de-
spite the relatively small number of compounds in the anal-
ysis, the diverse studies submitted to the CTD, and despite
the compounds with the same MOA having different chem-
ical structural features. Results of the SEURAT-1 high-
throughput ‘omics profiling experiments obtained from
treatments of the cellular model systems with the gold
compounds and submitted to the TBDW can be analyzed
in the same fashion.
The use of the CTD to analyze MOAs relevant to SEURAT-
1 gold compounds also illustrates how statistically signifi-
cant chemical-gene associations can be mined at the gene-
level and connected to MOAs via GO categories. Such asso-
ciations, if derived using a sufficiently large set of com-
pounds to ensure specificity, can be tentatively considered
biomarkers for the detection of toxicologically relevant
MOAs. MOA-specific genes and pathways that are detected
across several model systems or in the highest quality ones
would then form a basis for designing in vitro reporter
assays, such as those that are envisioned for further devel-
opments related to SEURAT-1 and its extensions.
The ultimate goal would be to fully recreate human in
vivo conditions in culture but the more realistic goal of
SEURAT-1 is to work towards animal-free repeated-dose
toxicity testing of chemical entities overall. Establishing cel-
lular models that enable determination of toxicity relevant
modes-of-action in a reproducible manner represents an
important step on the way.
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